Insulin resistance following continuous, chronic olanzapine treatment: An animal model

Schizophrenia Research

Volumn 104, Issue 1-3, 2008, Pages 23-30

  Chintoh, Araba F ^a,b   Mann, Steve W ^a,b   Lam, Tony K T ^a   Giacca, Adria ^a   Remington, Gary ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atypical antipsychotics; Insulin resistance; Olanzapine; Osmotic mini pump; Weight

Indexed keywords

GLUCOSE; OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE MODEL; DRUG MEGADOSE; EXPERIMENTAL RAT; FEMALE; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE UTILIZATION; INSULIN RELEASE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID STORAGE; LIVER METABOLISM; LOCOMOTION; LOW DRUG DOSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY WEIGHT; C-PEPTIDE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HYPERINSULINISM; INSULIN RESISTANCE; LOCOMOTION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 50249172922     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.06.006     Document Type: Article

References (34)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999) 1686-1696
2. Ader M., Kim S.P., Catalano K.J., Ionut V., Hucking K., Richey J.M., Kabir M., and Berbman R.N. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54 (2005) 862-871
3. Baptista T., Lacruz A., Paez X., Hernandez L., and Beaulieu S. The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?. Eur. J. Pharmacol. 447 (2002) 91-98
4. Bergman R.N., and Ader M. Atypical antipsychotics and glucose homeostasis. J. Clin. Psychiatry 66 (2005) 504-514
5. Casey D.E. Side effect profiles of new antipsychotic agents. J. Clin. Psychiatry 57 Suppl 11 (1996) 40-45
6. Chiu J.A., and Franklin R.B. Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. J. Pharm. Biomed. Anal. 14 (1996) 609-615
7. Elahi D. In praise of the hyperglycemic clamp. A method for assessment if beta-cell sensitivity and insulin resistance. Diabetes. Care. 19 (1996) 278-286
8. Faulkner G., Cohn T., Remington G., and Irving H. Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophr. Res. 90 (2007) 174-178
9. Fell M.J., Gibson R., McDermott E., Sisodia G., Marshall K.M., and Neill J.C. Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Behav. Brain. Res. 160 (2005) 338-343
10. Finegood D.T., Bergman R.N., and Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 36 (1987) 914-924
11. Goudie A.J., Smith J.A., and Halford J.C. Characterization of olanzapine-induced weight gain in rats. J. Psychopharmacol. 16 (2002) 291-296
12. Henderson D.C., Cagliero E., Gray C., Narsallah R.A., Hayden D.L., Schoenfeld D.A., and Goff D.C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am. J. Psychiatry 6 (2000) 975-981
13. Houseknecht K.L., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., and Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32 (2007) 289-297
14. Johnson D.E., Yamazaki H., Ward K.M., Schmidt A.W., Level W.S., Treadway J.L., Gibbs E.M., Zawalich W.S., and Rollema H. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifuse drat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 54 (2005) 1552-1558
15. Kapur S., and Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 153 (1996) 466-476
16. Kapur S., and Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 50 (2001) 873-888
17. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305 (2003) 625-631
18. Masand P.S., Culpepper L., Henderson D., Lee S., Littrell K., Newcomer J.W., and Rasgon N. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectr. 10 Suppl 14 (2005) 1-15
19. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur. Neuropsychopharmacol. 14 (2004) 115-119
20. Minet-Ringuet J., Even P.C., Guesdon B., Tomé D., and de Beaurepaire F. Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behav. Brain Res. 163 (2005) 204-211
21. Newcomer J.W. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J. Clin. Psychiatry 65 Suppl 18 (2004) 36-46
22. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., and Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 59 (2002) 337-345
23. Perry P.J., Lund B.C., Sanger T., and Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J. Clin. Psychopharmacol. 21 (2001) 14-20
24. Petersen J.L., and McGuire D.K. Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implications and management. Diab. Vasc. Dis. Res. 2 (2005) 9-15
25. Ramankutty G. Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta. Psychiatr. Scand. 105 (2002) 235-236
26. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry 60 Suppl 10 (1999) 5-14
27. Rigalleau V., Gatta B., Bonnaud S., Masson M., Bourgeois M.L., Vergnot V., and Gin H. Diabetes as a result of atypical anti-psychotic drugs - a report of three cases. Diabet. Med. 17 (2000) 484-486
28. Selva K.A., and Scott S.M. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J. Pediatr. 138 (2001) 936-938
29. Sernyak M.J., Gulanski B., and Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J. Clin. Psychiatry 66 (2005) 1463-1467
30. Stetten D., Welt I.D., Ingle D.J., and Moreley E.H. Rates of glucose production and oxidation in normal and diabetic rats. J. Biol. Chem. 192 (1951) 817-830
31. Stolic M., Russell, Hutley L., Fielding G., Hay J., MacDOnald G., Whitehead J., and Prins J. Glucose uptake and insulin action in human adipose tissue - influence of BMI, anatomical deport and body fat distribution. Int. J. Obes. Relat. Metab. Disord. 26 (2002) 17-23
32. Uwaifo G.I., Parikh S.J., Keil M., Elberg J., Chin J., and Yanovski J.A. Comparison of insulin sensitivity, clearance and secretion estimates using euglycemic and hyperglycemic clamps. J. Clin. Endocrinol. Metab. 87 (2002) 2899-2905
33. Wu R.R., Zhao J.P., Liu Z.N., Zhai J.G., Guo X.F., Guo W.B., and Tang J.S. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 186 (2006) 572-578
34. Zipursky R.B., Gu H., Green A.I., Perkins D.O., Tohen M.F., McEvoy J.P., Strakowski S.M., Sharma T., Kahn R.S., Gur R.E., Tollefson G.D., and Leiberman J.A. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br. J. Psychiatry 187 (2005) 537-543